Healthy Skepticism
Join us to help reduce harm from misleading health information.
Increase font size   Decrease font size   Print-friendly view   Print
Register Log in

Healthy Skepticism Library

Items published during the years 2000 to 2009

There are 14385 items in the Healthy Skepticism Library that were published during the years 2000 to 2009.

Page 2 of 144 pages  < 1 2 3 4 >  Last ›

Former Johnson & Johnson exec charged in Britain
Business Week 2009 Dec 1

Goldstein J
How a Decades-Old Drug Is Still a Patented Blockbuster
The Wall Street Journal Blog 2009 Dec 1

Hall DV, Jones SC, Iverson DC
Content analysis of disease awareness advertisements in popular Australian women's magazines
Med J Aust 2009 Dec 1; 191:(11/12):625-629

López Hidalgo MJ, Aguado Gómez A, Sánchez Ruiz M, García-Moreno Rodríguez G, Alejandre Lázaro G.
[How are the websites of pharmaceutical companies directed at users?]
Aten Primaria 2009 Dec 1;

Price DW, Raebel MA, Conner DA, Wright LA, Carroll NM.
Pharmaceuticals from development to practice: learnings from an online curriculum.
Am J Manag Care 2009 Dec 1; 15:(12):e109-14

Vitry AI.
Does direct-to-consumer prescription drug advertising do more harm than good?
Ann Intern Med 2009 Dec 1; 151:(11):823-4

Renckens CNM
In the Interest of All Who Value Their Purse and Their Health
Dutch Society Against Quackery 2009 Dec 1; 32:(4):343-348

The Differing Views Of Using Social Media In Pharma
Life Science Leader Magazine 2009 Dec

Atkinson JDM, Jones R
Intellectual property and its role in the pharmaceutical industry
Future Medicinal Chemistry 2009 Dec; 1:(9):1547-1550

Mintzes B, Mangin D
Opinion: Direct-to-consumer advertising of prescription medicines: a counter argument
Future Medicinal Chemistry 2009 Dec; 1:(9):1555-1560

Kennedy MS.
If it's too good to be true, it probably is.
Am J Nurs 2009 Dec; 109:(12):7;jsessionid=LQGJ0vvkQvM2lp0DDMkV0kPBmTmKpRfm4wJGhnQJ4KMqVNFGtHvG!797288596!181195629!8091!-1?issn=0002-936X&volume=109&issue=12&spage=7

Abraham J.
Partial progress: governing the pharmaceutical industry and the NHS, 1948-2008.
J Health Polit Policy Law 2009 Dec; 34:(6):931-77

Lupton JR.
Scientific substantiation of claims in the USA: focus on functional foods.
Eur J Nutr 2009 Dec; 48:

Muller N.
The age of social media and marketing--for sale: incontinence drugs and devices.
Ostomy Wound Manage 2009 Dec; 55:(12):23

Consumers Pay Little or No Attention to Drug Company's Advertised Risk Disclosures, Latest Under the Skin Study from ORC Guideline Finds
Pharma Live 2009 Nov 30

Heisel W
The Mittleman Files, Part 2: Just another day on the ghostwriting assembly line
Reporting on Health: Antidote: New Ways to Investigate Untold Health Stories 2009 Nov 30

Consumers Pay Little or No Attention to Drug Company’s Advertised Risk Disclosures, Latest Under the Skin Study from ORC Guideline Finds
Opinion Research Corporation 2009 Nov 30

Mundy A
How Industry Spends $1 Billion a Year on Continuing Medical Ed.
The Wall Street Journal Blog 2009 Nov 30

Poses RM
How Industry Views the Research It Sponsors
Health Care Renewal Blog 2009 Nov 30

Lawton V
Is the conflict of interest unacceptable when drug companies conduct trials on their own drugs? No
BMJ 2009 Nov 29; 339:

Goldacre B
Is the conflict of interest unacceptable when drug companies conduct trials on their own drugs? Yes
BMJ 2009 Nov 29; 339:

Jack A
The fall of the world’s best-selling drug
The Finanical Times 2009 Nov 28

Davidson R
Are Big Pharma and the PDUFA to Blame for Healthcare Mess?
OpEdNews 2009 Nov 27

Poses RM
More Evidence for Suppression of Research: the Case of Lamictal for Depression
Health Care Renewal Blog 2009 Nov 27

Brody H
Another Example of Spin in Published Results of Industry-Sponsored Clinical Trials
Hooked: Ethics, Medicine and Pharma 2009 Nov 27

Ecuador overrides 2,000 pharma patents
PM Live 2009 Nov 26,000_pharma_patents

Song F, Parekh-Bhurke S, Hooper L, Loke YK, Ryder JJ, Sutton AJ, Hing CB, Harvey I
Extent of publication bias in different categories of research cohorts: a meta-analysis of empirical studies
BMC Medical Research Methodology 2009 Nov 26; 9:(79):

Leach B
Boots: 'we sell homeopathic remedies because they sell, not because they work'
The Daily Telegraph 2009 Nov 26

Silverman E
A Petition To Keep Pfizer Exec Off Canadian Board
Pharmalot 2009 Nov 25

Berkovic N
ADHD panel's drugs links being properly `managed'
The Australian 2009 Nov 25

Iskowitz M
Health ed. firms benefit from pharma's compliance woes
Medical Marketing & Media 2009 Nov 25

Blum JA, Freeman K, Dart RC, Cooper RJ
Requirements and Definitions in Conflict of Interest Policies of Medical Journals
JAMA 2009 Nov 25; 302:(20):2230-2234.

Antidepressants: benefit of reboxetine not proven
Institute for Quality and Efficiency in Health Care 2009 Nov 24

Edwards J
Study Showing Drug Ads Are Linked to Higher Prices Has Flaws
BNet 2009 Nov 24

Law MR, Soumerai SB, Adams AS, Majumdar SR
Costs and Consequences of Direct-to-Consumer Advertising for Clopidogrel in Medicaid
Arch Intern Med 2009 Nov 23; 169:(21):1969-1974.

Drug Ads Ineffective for Boosting Sales, Could Cost Taxpayers: UBC-Harvard Study
PharmaLive 2009 Nov 23

Ross JS, Madigan D, Hill KP, Egilman DS, Wang Y, Krumholz HM
Pooled Analysis of Rofecoxib Placebo-Controlled Clinical Trial Data
Arch Intern Med 2009 Nov 23; 169:(21):1976-1985.

Woloshin S, Schwartz LM
Bringing the FDA's Information to Market
Arch Intern Med 2009 Nov 23; 169:(21):1985-1987

Direct-to-Consumer Offers for Free and Discounted Medications on the Internet: A Content Analysis of 'e-Samples'
Arch Intern Med 2009 Nov 23; 169:(21):2024-2030.

Taylor L
US drugmakers' fury over price probe demands
Pharma Times 2009 Nov 23

Sikora K
ADHD guidelines pulled after payment scandal
The Daily Telegraph 2009 Nov 23

Hamza W
Pharma cos pressurise govt to legalise DTCAs
The Nation 2009 Nov 22

Pharma, Evidence, and Trust
Evidence in Medicine 2009 Nov 21

Damman OC, Hendriks M, Rademakers J, Delnoij DMJ, Groenewegen PP
How do healthcare consumers process and evaluate comparative healthcare information? A qualitative study using cognitive interviews
BMC Public Health 2009 Nov 20; 9:(423):

Feeley J, Cronin Fisk M
AstraZeneca Judge to Urge Return of Seroquel Cases to Courts 2009 Nov 19

Goldstein J
In Medical Research, Who Should Define Conflict of Interest?
The Wall Street Journal Blog 2009 Nov 19

Harris G
Academic Researchers’ Conflicts of Interest Go Unreported
The New York Times 2009 Nov 18

Lazarus D
The danger of marketing prescription drugs online
The LA Times 2009 Nov 18,0,4079474,full.column

Edwards J
Bayer Tries New Google Drug Ad Format But Lawyers Spoil the Party
BNet 2009 Nov 18

Wilson D
Rising Prices of Drugs Lead to Call for Inquiry
The New York Times 2009 Nov 18

Selker HP, Wood AJJ
Industry Influence on Comparative-Effectiveness Research Funded through Health Care Reform
NEJM 2009 Nov 18;

Rosenberg M
Pediatric Zyprexa Brochures Embarrass British Health Service
OpEdNews 2009 Nov 18

Future Physicians Develop Conflict Of Interest Curriculum For Nation's Academic Medical Centers
Medical News Today 2009 Nov 17

McMahon AD, Conway DI, MacDonald TM, McInnes GT
The Unintended Consequences of Clinical Trials Regulations
PLoS Med 2009 Nov 17;

Wilson D
Medical Schools Quizzed on Ghostwriting
The New York Times 2009 Nov 17

Silverman E
100 Researchers Ask NIH To Fund Ethics Research
Pharmalot 2009 Nov 17

O'Brien J
O'Brien: Just say no to online drug ads
Mercury News 2009 Nov 17

Basken C
Ethicists Prod NIH to Spend Money Investigating Conflicts of Interest
The Chronicle of Higher Education 2009 Nov 17

Study says drug does little, proving need for more testing
The Boston Globe 2009 Nov 16

Wilson D
Drug Makers Raise Prices in Face of Health Care Reform
The New York Times 2009 Nov 15

Herper M
Another Vytorin Mess For Merck
Forbes 2009 Nov 15

Pear R
In House, Many Spoke With One Voice: Lobbyists’
The New York Times 2009 Nov 14

Silverman E
House Bill Wants Pharma To Disclose CME Funding
Pharmalot 2009 Nov 13

Goldstein J
Google’s Pitch to FDA for Online Drug Ads
The Wall Street Journal Blog 2009 Nov 13

Arnold M
Outlook 2010: A New Dawn
Medical Marketing & Media 2009 Nov 13

Johnson LA
Review: Reporting on Pfizer drug studies fudged
The Associated Press 2009 Nov 12

Vedula SS, Bero L, Scherer RW, Dickersin K
Outcome Reporting in Industry-Sponsored Trials of Gabapentin for Off-Label Use
NEJM 2009 Nov 12; 361:(20):1963-1971

Grogan K
Pfizer critical of 'selective outcome reporting' study
Pharma Times 2009 Nov 12

Bowcott O
Chemical restraints killing dementia patients
The Guardian 2009 Nov 12

Steel E
Drug Makers to Press for Guidance on Web Marketing
The Wall Street Journal 2009 Nov 12B4

Seetharaman D
UPDATE 1-U.S. FDA tackles gray area of social media
Reuters 2009 Nov 12

Scarcella M
DOJ Targets Pharmaceutical Industry for FCPA Enforcement
The Legal Times Blog 2009 Nov 12

Hensley S
Google Has A Plan For Safer, More Useful Online Drug Ads
npr 2009 Nov 12

Lewis-Hall FC
Promotion of FDA-Regulated Medical Products Using the Internet and Social Media Tools
National Transportation Safety Board Conference Center 2009 Nov 12

US Department of Health and Human Services FDA
Promotion of Food and Drug Administration-Regulated Medical Products Using the Internet and Social Media Tools; Notice of Public Hearing
2009 Nov 12

Brody H
COI: Define It Narrowly Enough and It Goes Away
Hooked: Ethics, Medicine and Pharma 2009 Nov 12

Thomaselli R
PhRMA Proposes FDA-Approved Logo for Marketing in Social Media Industry, Government Grapple With New Frontier in Day 1 of Hearings
The Advertising Age 2009 Nov 12

Phillips D
Biogen Idec's Social Media Ties Save Tysabri Again; FDA Watching
BNet 2009 Nov 12

O'Hara M
Dangers of giving air time to TV's drug pushers
The Guardian 2009 Nov 11

Irwin T
FDA Ponders Rules For Online Pharma Ads
MarketingDaily 2009 Nov 11

Silverman E
What Changes? Pfizer Fudged Neurontin Studies
Pharmalot 2009 Nov 11

Grant B
The blogopharmasphere?
The Scientist 2009 Nov 10

Iskowitz M
Bid to restrict industry-backed CME rebuffed, again
Medical Marketing & Media 2009 Nov 10

Gérvas J, Wright J
Please may we have an RCT now?
BMJ 2009 Nov 10; 339:

Silverman E
So Maybe DTC Ads Aren’t Worth It, After All
Pharmalot 2009 Nov 10

Staton T
Justice eyes marketing at J&J, Forest
Fierce Pharma 2009 Nov 10

Seetharaman D
US drugmakers urge FDA safety logo for Internet
Reuters 2009 Nov 9

Evans D
Pfizer Broke the Law by Promoting Drugs for Unapproved Uses 2009 Nov 9

Silverman E
Forest Labs In Tentative Deal Over Marketing Probe
Pharmalot 2009 Nov 9

Jewett C, Roe S,
Doctor-drugmaker ties: Psychiatrist Dr. Michael Reinstein received nearly $500,000 from antipsychotic drug's manufacturer
The Chicago Tribune 2009 Nov 9,0,172967,full.story

Verilogue Study: Does Higher DTC Spending Result in Positive Patient-Physician Conversations?
Verilogue 2009 11 09

Loftus P
Forest Labs In Tentative Pact To Settle US Civil Probe >FRX
The Wall Street Journal 2009 Nov 9

Shrader-Frechette K.
Climate Change, Nuclear Economics, and Conflicts of Interest.
Sci Eng Ethics 2009 Nov 8;

Silverman E
Abbott Labs Probed Over Depakote Marketing
Pharmalot 2009 Nov 6

Silverman E
Marketing Nexium As Superior To Prilosec Was OK
Pharmalot 2009 Nov 6

Edwards J
AstraZeneca's New Blog Is Slammed by Critics
BNet 2009 Nov 6

Dorschner J
Controversial psychiatrist to head UM medical school department
The Miami Herald 2009 Nov 5

Arnold M
CEOs trump movie stars among celeb endorsers, says survey
Medical Marketing & Media 2009 Nov 4

Goldstein J
Antipsychotic Drugs, Elderly Patients and Omnicare’s Settlement
The Wall Street Journal Blog 2009 Nov 4

Weintraub A
Ask Your Doctor If This Ad Is Right for You
Business Week 2009 Nov 4

Page 2 of 144 pages  < 1 2 3 4 >  Last ›


  Healthy Skepticism on RSS   Healthy Skepticism on Facebook   Healthy Skepticism on Twitter

Click to Register

(read more)

Click to Log in
for free access to more features of this website.

Forgot your username or password?

You are invited to
apply for membership
of Healthy Skepticism,
if you support our aims.

Pay a subscription

Support our work with a donation

Buy Healthy Skepticism T Shirts

If there is something you don't like, please tell us. If you like our work, please tell others.

Far too large a section of the treatment of disease is to-day controlled by the big manufacturing pharmacists, who have enslaved us in a plausible pseudo-science...
The blind faith which some men have in medicines illustrates too often the greatest of all human capacities - the capacity for self deception...
Some one will say, Is this all your science has to tell us? Is this the outcome of decades of good clinical work, of patient study of the disease, of anxious trial in such good faith of so many drugs? Give us back the childlike trust of the fathers in antimony and in the lancet rather than this cold nihilism. Not at all! Let us accept the truth, however unpleasant it may be, and with the death rate staring us in the face, let us not be deceived with vain fancies...
we need a stern, iconoclastic spirit which leads, not to nihilism, but to an active skepticism - not the passive skepticism, born of despair, but the active skepticism born of a knowledge that recognizes its limitations and knows full well that only in this attitude of mind can true progress be made.
- William Osler 1909